TheraSonic

The brain is protected from pathogens and certain molecules by the blood-brain barrier, complicating the development of effective drugs for diseases like brain cancers.

TheraSonic, a startup resulting from 15 years of research at CEA Saclay and CNRS, develops a medical device using transcranial focused ultrasound to make this barrier permeable to drugs and allow their delivery. This non-invasive medical device, combining a robotic arm and a neuronavigation system, precisely targets areas of the brain, opening new perspectives for treating brain metastases. A patented ultrasonic dosimetry system ensures the device’s safety.

Involved for several months alongside the scientific team, M2care invests financially and humanly in the creation of TheraSonic, aiming to conduct a first human study by 2025.